Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 8/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | USP5 | P45974 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2923903 | 0.80 | USP5 (0.64) | HSD17B3L3MBTL1HTR7NPC1USP5 | |
| SCHEMBL10520447 | 0.78 | ALDH1A1 (0.47) | RAB9ASMN1; SMN2 | |
| SCHEMBL3682043 | 0.78 | USP5 (0.47) | HSD17B3L3MBTL1HTR7NPC1USP5 | |
| SCHEMBL8072880 | 0.78 | USP5 (0.47) | HSD17B3L3MBTL1HTR7NPC1USP5 | |
| SCHEMBL3671743 | 0.76 | USP5 (0.50) | L3MBTL1NPC1USP5RAB9AHPGD | |
| SCHEMBL27724305 | 0.76 | USP5 (0.46) | HSD17B3L3MBTL1HTR7NPC1USP5 | |
| SCHEMBL29023170 | 0.76 | NPC1 (0.47) | HSD17B3L3MBTL1HTR7NPC1USP5 | |
| SCHEMBL3671788 | 0.76 | L3MBTL1 (0.51) | HSD17B3L3MBTL1HTR7NPC1USP5 | |
| SCHEMBL27707793 | 0.76 | L3MBTL1 (0.65) | HSD17B3L3MBTL1HTR7NPC1 | |
| SCHEMBL11484918 | 0.76 | HSD17B3 (0.61) | HSD17B3L3MBTL1HTR7NPC1USP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566717-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20080275238-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | PALLE VENKATA | 2008-11-06 | — | — | US | disclosed |
| US-20070155728-A1 | Substituted Heterocyclic Compounds | PALLE VENKATA | 2007-07-05 | — | — | US | disclosed |
| US-7205303-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20040176356-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176356-A1 | Substituted heterocyclic compounds | KCNH1, KCNJ2, SCN5A | HSD17B3 883/4885L3MBTL1 970/4885HTR7 2855/4885 |
| US-20080275238-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, SDHA, COQ8A | HSD17B3 510/4885L3MBTL1 1085/4885HTR7 3329/4885 |
| US-20070155728-A1 | Substituted Heterocyclic Compounds | KCNH1, SDHA, COQ8A | HSD17B3 510/4885L3MBTL1 1085/4885HTR7 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.